Mon, Jul 28, 2014, 9:04 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Hemispherx Biopharma, Inc. Message Board

  • netprophecy2 netprophecy2 Jun 8, 2006 12:59 AM Flag

    note to carter

    why have full results of the trials not been released yet? what is wrong?

    wall street and the governmental agencies of the world do not regard either drug as meaningful or worthy of investment at this point.

    it is quite likely that by the time ampligen or alferon is approved and able to be produced, that it will be a moot point.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hey net....

      you have proven yourself to be a moron more than once....

      Here are the results of a similar drug...

      Remodulin

      http://www.unither.com/Files/10.15.01.pr.pdf

      Please demonstrate with this drug what you mean????

      tia...

      • 1 Reply to jonjonson1234
      • To make it easy....

        please use any of the similar drugs to show what HEB is not doing ...

        tia.....


        By comparison, analysis of seven (7) recent clinical studies, which resulted in commercial approvals (or �approvable� letters) for various drugs used in these other allied disease categories (both CHF and AH), showed much lower magnitudes of physical performance improvements due to therapeutic interventions. For example, in CHF: Fosinopril (6.7% improvement), Captopril (6.2%), Ranolazine (6.5%) and Ranolazine (5.7%); in AI, Tracleer (10.6% improvement), Remodulin (8.0%), Remodulin (4.1%) and Remodulin (6.1%). All therapeutic measurements in these seven (7) other studies were determined by exercise treadmill testing (or extent of walking), similar or identical to the therapeutic endpoint used in the CFS study.

 
HEB
0.264-0.006(-2.19%)Jul 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.